Cathay End Period Cash Flow from 2010 to 2024

688065 Stock   42.84  0.22  0.51%   
Cathay Biotech's End Period Cash Flow is increasing over the years with slightly volatile fluctuation. Overall, End Period Cash Flow is expected to go to about 5.8 B this year. From 2010 to 2024 Cathay Biotech End Period Cash Flow quarterly data regression line had arithmetic mean of  2,348,805,872 and r-squared of  0.59. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
B
Current Value
5.8 B
Quarterly Volatility
3.1 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cathay Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cathay Biotech's main balance sheet or income statement drivers, such as Tax Provision of 56.8 M, Net Interest Income of 134.7 M or Interest Income of 156.9 M, as well as many indicators such as . Cathay financial statements analysis is a perfect complement when working with Cathay Biotech Valuation or Volatility modules.
  
This module can also supplement various Cathay Biotech Technical models . Check out the analysis of Cathay Biotech Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Cathay Stock

Cathay Biotech financial ratios help investors to determine whether Cathay Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cathay with respect to the benefits of owning Cathay Biotech security.